Phaseline

Companies › AskGene Pharma

AskGene Pharma: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASKB589–Phase 3Gastroesophageal Junction Adenocarcinoma; Gastric CancerDec 2026
ASKG915–Phase 1Advanced Solid TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05632939ASKB589Phase 1Gastric CancerOncologyOct 2025
NCT06206733ASKB589Phase 3Gastroesophageal Junction AdenocarcinomaOncologyDec 2026
NCT05867420ASKG915Phase 1Advanced Solid TumorsOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Lepu Biopharma Coherus Oncology OncoC4 Tesaro GC Cell

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.